Study of Safety and Efficiency of the Drug Reamberin® in the Intensive Care of Patients With Acute Ethanol Intoxication

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

296 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-09-15

Study Completion Date

2025-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Acute ethanol intoxication is the most frequent pathologic condition developing in subjects using alcohol. The severity of disorders in acute alcohol intoxication is determined, first of all, by the quantity of consumed alcohol and the duration of the toxic effect. When toxic doses of alcohol are taken per os, a life-threatening condition develops, which is manifested by consciousness depression and severe metabolism disorders. Reamberin (1.5 % meglumine sodium succinate solution) is an infusion solution with a balanced electrolyte composition and succinic acid, which is recommended for rehydration and detoxication in patients with intoxications of different genesis. The metabolic effect of Reamberin helps restore homeostasis and improve the natural organism detoxication. The investigators suppose that administration of Reamberin to patients with acute ethanol intoxication will make it possible to improve the treatment quality as compared to the standard therapy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Clinical Trial to Evaluate the Safety and Efficacy of ADX-629 in in Subjects With Elevated Ethanol Levels

NCT05487404

Ethanol Intoxication

COMPLETED PHASE1/PHASE2

Combined Pharmacotherapies for Alcoholism (Naltrexone/Ondansetron)

NCT00027079

Alcoholism

COMPLETED PHASE2

Effect of Varenicline on Fixed-Dose Alcohol Administration in Participants With Alcohol Use Disorders

NCT01000987

Alcohol Reactivity

COMPLETED PHASE2

Treatment Of Alcohol Withdrawal Syndrome: Dexmedetomidine Vs Diazepam In A Hospital O'horán

NCT03877120

Alcohol Withdrawal Delirium

COMPLETED PHASE4

Prevalence of Chronic Inebriates to the Emergency Department and Suitability for Sobering House Services

NCT01783223

Alcohol Intoxication

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

All drugs will be administered according to the instruction for medical use and conventional clinical practice.

The decision on the selection of therapy shall be made by a medical investigator irrespective of the protocol before the inclusion of a patient in the study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ethanol Intoxication

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

The control group

Standard therapy

No interventions assigned to this group

The test group

Standard therapy + Reamberin

Reamberin

Intervention Type DRUG

Reamberin® in the average daily dose of 10 ml/kg daily

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Reamberin

Reamberin® in the average daily dose of 10 ml/kg daily

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male and female patients aged from 22 to 65 years.
2. It is planned to administer one of the following treatment types to the patient, as part of the routine clinical practice:

* Standard fluid administration + Reamberin®. It is planned to administer the drug Reamberin® in the average daily dose of 10 ml/kg daily for the whole period of treatment at ICU.
* Standard fluid administration (without the use of the drug Reamberin®).
3. Primary diagnosis:

* toxic effect of ethanol (T51.0 according to ICD-10);
* acute intoxication caused by the simultaneous use of several narcotic drugs and the use of other psychoactive substances2 (F19.0 according to ICD-10);
* mental and behavioral disorders caused by alcohol use. Acute intoxication (F10.0 according to ICD-10).
4. Blood ethanol concentration: 1.5 ‰ (per mille) and more.
5. Consciousness depression (Glasgow Coma Score = 6-12)
6. Laboratory signs of a shift in the acid-base balance towards metabolic acidosis: base deficit (BE) of venous blood less than -2.2 mmol/l).
7. Availability of the written consent of the patient or his (her) legally authorized representative.

Exclusion Criteria

1. Use of other drugs containing malate or succinate.
2. Consciousness depression with Glasgow Coma Score of lower than 6.
3. Intoxication with addictive substances and psychotropic drugs.
4. Shock.
5. Body weight of less than 50 kg or more than 120 kg.
6. Data on the presence of malignant neoplasms.
7. Decompensation of chronic pulmonary diseases with the development of respiratory failure of degree II-III as at the time of inclusion in the study.
8. Pregnancy, breast feeding.
9. Craniocerebral injury or polytrauma.
10. Acute cerebrovascular accident.
11. Infection-inflammatory disease of CNS (meningitis, encephalitis etc.) and other variants of CNS function disorder not associated with ethanol intoxication.
12. Respiratory impairment requiring ALV.
13. Contraindications mentioned in the approved instructions for the use of the drugs used in the study.
14. A disease or the use of drugs, which, in the physician's opinion, can influence safety, tolerance and efficiency of the study drugs.

Minimum Eligible Age

22 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No